Clinical Trial

Pancreatic Cancer Early Detection Consortium

Study acronym: PRECEDE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Protocol Amendment History 64 amendments
This ClinicalTrials.gov record has been amended 64 times since 2021-07-19; most recent amendment 2026-07-21.
Trial Details
NCT Number NCT04970056
Lead Sponsor Arbor Research Collaborative for Health
Conditions Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Enrollment 20,000 participants
Start Date 2020-09-18
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22